Highest-materiality recent filing
908 Devices Q1 rev +14% to $13.4M, raises FY26 outlook; buys NIRLAB for $15M
Q1 revenue $13.4M (+14% YoY); recurring revenue $4.0M (30% of total); gross margin 51%, adj. 57%.
908 Devices Q4 rev $17.4M (+21% YoY); positive adj. EBITDA; FY2026 guide $64.5-67.5M
Q4 revenue $17.4M (up 21% YoY); full-year revenue $56.2M (up 18% YoY).
908 Devices Q4 revenue $17.2M (+20% YoY); FY2025 ~$56M (+17%), positive Adj. EBITDA in Q4
Q4 2025 revenue ~$17.2M versus $14.3M in Q4 2024, growth of ~20%.
Q3 revenue of $14.0M, down 4% YoY; first nine months revenue up 16% to $38.8M; installed base grew 27% YoY to 3,512 devices.
908 Devices Q2 revenue $13.0M (+14% YoY); raises 2025 revenue outlook to $54-56M
Revenue from continuing ops $13.0M (+14% YoY); recurring revenue $4.7M (+28%, 36% of total).
908 Devices appoints Dr. Brandi Vann to board; Jeff George resigns
Jeff George resigned from Board effective July 31, 2025; departure follows sale of bioprocessing portfolio.
Board changes: Eisenberg resigns, co-founder Brown appointed director
Marcia Eisenberg resigned from board and compensation committee effective June 12, 2025.
908 Devices stockholders re-elect three Class II directors and ratify auditor at annual meeting
Directors Kevin Knopp, Tony Hunt, and Mark Spoto re-elected with 17.1M–17.3M votes for each; broker non-votes of 6.5M.
On June 13, 2025, Christopher D. Brown was appointed to the Board to fill the vacancy created following Ms. Eisenberg’s resignation.
On June 12, 2025, Marcia Eisenberg resigned from the Board of Directors (the “Board”) of 908 Devices Inc. (the “Company”) and the Compensation Committee of the Board. Her resignation was effective on June 12, 2025 at 5:00 p.m. Eastern Time.
Max materiality 0.85 · Median 0.65 · Most common event earnings